1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Publication
, Conference
Catenacci, DV; Strickler, JH; Shitara, K; Nakamura, Y; Janjigian, YY; Barzi, A; Bekaii-Saab, T; Lenz, HJ; Chung, HC; Tabernero, J; Yoshino, T ...
Published in: Annals of Oncology
September 2021
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S1071 / S1072
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Catenacci, D. V., Strickler, J. H., Shitara, K., Nakamura, Y., Janjigian, Y. Y., Barzi, A., … Marshall, J. L. (2021). 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. In Annals of Oncology (Vol. 32, pp. S1071–S1072). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1543
Catenacci, D. V., J. H. Strickler, K. Shitara, Y. Nakamura, Y. Y. Janjigian, A. Barzi, T. Bekaii-Saab, et al. “1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress.” In Annals of Oncology, 32:S1071–72. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1543.
Catenacci DV, Strickler JH, Shitara K, Nakamura Y, Janjigian YY, Barzi A, et al. 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. In: Annals of Oncology. Elsevier BV; 2021. p. S1071–2.
Catenacci, D. V., et al. “1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S1071–72. Crossref, doi:10.1016/j.annonc.2021.08.1543.
Catenacci DV, Strickler JH, Shitara K, Nakamura Y, Janjigian YY, Barzi A, Bekaii-Saab T, Lenz HJ, Chung HC, Tabernero J, Yoshino T, Siena S, Mayor JG, Palanca-Wessels MC, Xie D, Marshall JL. 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. Annals of Oncology. Elsevier BV; 2021. p. S1071–S1072.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S1071 / S1072
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis